Bengaluru, Dec. 30 -- The shares of this company, which develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets, are in focus after it announces an entry into a license that will boost its diabetes portfolio.

With a market capitalization of Rs 94,548 crore, Lupin Ltd's shares on Tuesday made a day high of Rs 2,099.60, up by 1 percent from its previous day's closing price of Rs 2,079.50 per share. The shares have given a return of 106 percent over a period of five years.

Lupin has signed an exclusive agreement with China-based Gan & Lee Pharmaceuticals to bring Bofanglutide, a new long-acting GLP-1 injection, to India. The deal gives Lupin sole rights to supply an...